esearch demonstrating the remarkable cancer-killing power of genetically rewired white blood cells — known as CAR-T therapy — has long grabbed the spotlight at the annual meeting of the American Society of Hematology.

This year, though, the debate is no longer about whether or not CAR-T kills cancer. New research to be presented at the conference, kicking off Saturday in Atlanta, will focus instead on the long-term durability of CAR-T, the potential to target different types of blood cancers, and the feasibility of treating large numbers of patients scattered across the globe.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.